World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
113
Citations
45512
World Ranking
434
National Ranking
266

Medicine

D-Index
114
Citations
45688
World Ranking
4764
National Ranking
2583

David B. Weiner publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where David B. Weiner sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 784 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

David B. Weiner D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where David B. Weiner sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 113 D-Index — 91st percentile

91% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2011 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

David B. Weiner is affiliated with The Wistar Institute in the United States. Their research spans multiple domains within medicine, immunology and microbiology, and biochemistry, genetics, and molecular biology. They have contributed significantly to subfields including infectious diseases, immunology, molecular biology, oncology, and epidemiology.

Their recent scientific papers cover diverse topics in immunology and infectious diseases, with a focus on COVID-19 and vaccine development. Notable publications include:

  • Immunogenicity of a DNA vaccine candidate for COVID-19 (2020) published in Nature Communications
  • Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial (2020) published in EClinicalMedicine
  • DNA vaccines: prime time is now (2020) published in Current Opinion in Immunology
  • Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy (2021) published in Nature Communications
  • Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial (2024) published in Nature Medicine

Their research interests prominently include SARS-CoV-2 and COVID-19 research, immunotherapy and immune responses, vaccines and immunoinformatics approaches, CAR-T cell therapy research, COVID-19 clinical research studies, monoclonal and polyclonal antibodies research, and RNA interference and gene delivery.

David B. Weiner frequently collaborates with other researchers in the field. Frequent co-authors include:

  • Ami Patel
  • Nicholas J. Tursi
  • Laurent Humeau
  • E. Gary
  • Kate E. Broderick

Their work is published regularly in journals and platforms such as Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), The Journal of Immunology, Frontiers in Immunology, and Nature Communications.

David B. Weiner was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 2011.

Best Publications

  • Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

    Erwei Song;Pengcheng Zhu;Sang Kyung Lee;Dipanjan Chowdhury

  • DNA vaccines: ready for prime time?

    Michele A. Kutzler;David B. Weiner

  • Gene inoculation generates immune responses against human immunodeficiency virus type 1.

    Bin Wang;Kenneth E. Ugen;Vasantha Srikantan;Michael G. Agadjanyan

  • Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

    Cornelia L Trimble;Matthew P Morrow;Kimberly A Kraynyak;Xuefei Shen

  • Innate Lymphoid Cells Promote Anatomical Containment of Lymphoid-Resident Commensal Bacteria

    Gregory F. Sonnenberg;Laurel A. Monticelli;Theresa Alenghat;Thomas C. Fung

  • First Human Trial of a DNA-Based Vaccine for Treatment of Human Immunodeficiency Virus Type 1 Infection: Safety and Host Response

    Rob Roy MacGregor;Jean D. Boyer;Kenneth E. Ugen;Kim E. Lacy

  • Immunogenicity of a DNA vaccine candidate for COVID-19.

    Trevor R.F. Smith;Ami Patel;Stephanie Ramos;Dustin Elwood

  • p185neu Expression in Human Lung Adenocarcinomas Predicts Shortened Survival

    Jeffrey A. Kern;David A. Schwartz;Joanne E. Nordberg;David B. Weiner

  • A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

    David B. Weiner;Jing Liu;Jeffrey A. Cohen;William V. Williams

  • Clinical Applications of DNA Vaccines: Current Progress

    Bernadette Ferraro;Matthew P. Morrow;Natalie A. Hutnick;Thomas H. Shin

  • Electroporation delivery of DNA vaccines: prospects for success

    Niranjan Y Sardesai;David B Weiner

  • Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.

    Jean D. Boyer;Kenneth E. Ugen;Bin Wang;Michael Agadjanyan

  • In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen.

    Jong J. Kim;Velpandi Ayyavoo;Mark L. Bagarazzi;Michael A. Chattergoon

  • Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

    Mark L. Bagarazzi;Jian Yan;Matthew P. Morrow;Xuefei Shen

  • Compositions and methods for delivery of genetic material

    David B. Weiner;William V. Williams;Bin Wang;Leslie R. Coney

  • DNA vaccination: antigen presentation and the induction of immunity.

    Devon J. Shedlock;David B. Weiner

  • Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1.

    David N. Levy;Yosef Refaeli;Rob Roy MacGregor;David B. Weiner

  • Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung

    David B. Weiner;Joanne Nordberg;Robert Robinson;Peter C. Nowell

  • HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B.

    Velpandi Ayyavoo;Artin Mahboubi;S. Mahalingam;R. Ramalingam;R. Ramalingam

  • Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

    Kayvon Modjarrad;Christine C. Roberts;Kristin T. Mills;Amy R. Castellano

  • Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1

    V. Yusibov;A. Modelska;K. Steplewski;M. Agadjanyan

Frequent Co-Authors

Karuppiah Muthumani
Karuppiah Muthumani The Wistar Institute
Jean D. Boyer
Jean D. Boyer Inovio Pharmaceuticals (United States)
William V. Williams
William V. Williams GlaxoSmithKline (United Kingdom)
Niranjan Y. Sardesai
Niranjan Y. Sardesai University of Pennsylvania
Kenneth E. Ugen
Kenneth E. Ugen University of South Florida
Mark I. Greene
Mark I. Greene University of Pennsylvania
Thomas Kieber-Emmons
Thomas Kieber-Emmons University of Arkansas for Medical Sciences
George N. Pavlakis
George N. Pavlakis Emory University
Mark G. Lewis
Mark G. Lewis Walter Reed Army Institute of Research
Gary Kobinger
Gary Kobinger The University of Texas Medical Branch at Galveston

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding into nursing roles offers diverse career opportunities. Many professionals pursue specialized certifications such as the cheapest pmhnp certificate programs, combining mental health expertise with immunological knowledge for holistic patient care.

Nursing professionals can also enhance their qualifications with advanced degrees, reflecting in competitive compensation. Checking the doctor of nursing practice salary across different states helps prospective students make informed decisions about where to study and work.

Transitioning between specialized nursing fields is common, and resources like the fnp to acute care np bridge program offer streamlined pathways for family nurse practitioners aiming to advance into acute care, a field closely tied to immunology in treating complex cases.

Lastly, accelerated programs such as the accelerated fnp courses provide an efficient route for students to quickly gain credentials and enter the workforce, blending immunology knowledge with family practice skills.

Best Scientists Citing David B. Weiner

Trending Scientists

Recently Published Articles